Scholar Rock (SRRK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order and conducted virtually, welcoming stockholders and guests.
Meeting held in accordance with bylaws and Delaware law, with formal business and Q&A phases outlined.
Agenda and rules of conduct provided to all participants, with instructions for submitting questions.
Board and executive committee updates
Directors and management team introduced, including key officers and outside counsel.
Board members present included the CEO, President of R&D, and several independent directors.
Corporate governance
Inspector of Elections appointed to oversee voting and quorum confirmed with over 114 million shares represented.
Voting procedures explained, allowing proxy and virtual ballot submissions.
Nominations for Class II directors closed with four current board members nominated for three-year terms.
Latest events from Scholar Rock
- Apitegromab nears FDA approval with dual manufacturing paths and strong launch readiness.SRRK
Canaccord Genuity's 46th Annual Growth Conference - FDA decision on apitegromab expected by September 30, 2026, with strong cash reserves and launch readiness.SRRK
Q2 2026 - Apitegromab targets broad SMA eligibility, with global launch expected in 2026 and pipeline expansion ahead.SRRK
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Dual-path regulatory strategy positions apitegromab for imminent global launch and strong growth.SRRK
Jefferies Global Healthcare Conference 2026 - First myostatin inhibitor for SMA nears launch, backed by strong demand and financial stability.SRRK
Bank of America Global Healthcare Conference 2026 - Apitegromab BLA accepted; strong cash reserves support 2026 launches amid rising net loss.SRRK
Q1 2026 - Q3 2025 net loss was $102.2M; apitegromab U.S. launch expected in 2026.SRRK
Q3 2025 - Apitegromab plus tirzepatide preserved lean mass and improved weight loss quality in obesity.SRRK
Study Update - Apitegromab nears FDA decision with Q3 2025 U.S. launch planned and strong cash reserves.SRRK
Q1 2025